findmyKOL
Clinical trialNCT07118670Active, not recruitingPhase 4Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

SponsorEdward Wood, MDEnrollment40Proliferative Diabetic Retinopathy (PDR)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Retina Consultants of Texas - Austin Retina Associates

    Austin, Texas, United States

  • Retina Consultants of Texas

    Bellaire, Texas, United States

  • Retina Consultants of Texas - San Antonio

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aflibercept →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Dec 2025
Primary completion
29 Feb 2028
Completion
30 Apr 2028
Last update posted
18 Mar 2026
Registered enrollment
40
Registry id
NCT07118670
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.